Richard A. Heyman, Director: Enliven Therapeutics ELVN Sell · Filed 24/10/17

Trade details

Type: Insider sale
Amount: $35,140.9
Shares · price: 1,270 sh · $27.67 a share
Held after: 124,490 sh
Stock: Enliven Therapeutics ELVN
Person: Richard A. HeymanDirector
Trade date: 24/10/15
Filed: 24/10/17
Days to filing: 2 days

Sold 1.0% of holdings

Share of holding sold: 1.0%

Enliven Therapeutics trades, last 26 weeks

What else happened in Enliven Therapeutics around then

Filed or reported within 30 days of the trade day · 24/09/15~24/11/14

Richard A. Heyman's recent trades

Richard A. HeymanDirector
Planned saleEnliven Therapeutics
Planned sale
Enliven Therapeutics
ELVN
$2.3M
38,000 sh
$2.3M
Filed 09/04
Traded 09/04
Richard A. HeymanDirector
Planned sale10b5-1 planOric Pharmaceuticals
Planned sale10b5-1 plan
Oric Pharmaceuticals
ORIC
$84K
7,000 sh
$84K
Filed 07/06
Traded 07/06
Richard A. HeymanDirector
Planned sale10b5-1 planOric Pharmaceuticals
Planned sale10b5-1 plan
Oric Pharmaceuticals
ORIC
$76.8K
6,400 sh
$76.8K
Filed 07/06
Traded 07/06
Richard A. HeymanDirector
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$32.2K
1,230 sh
$32.2K
Filed 02/19
Traded 02/17
Richard A. HeymanDirector
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$32.9K
1,230 sh
$32.9K
Filed 02/17
Traded 02/17